PRTK Annual EBITDA
-$44.90 M
-$4.21 M-10.36%
31 December 2022
Summary:
As of January 21, 2025, PRTK annual earnings before interest, taxes, depreciation & amortization is -$44.90 million, with the most recent change of -$4.21 million (-10.36%) on December 31, 2022. During the last 3 years, it has risen by +$67.19 million (+59.94%).PRTK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRTK Quarterly EBITDA
-$9.17 M
+$6.39 M+41.07%
30 June 2023
Summary:
As of January 21, 2025, PRTK quarterly earnings before interest, taxes, depreciation & amortization is -$9.17 million, with the most recent change of +$6.39 million (+41.07%) on June 30, 2023. Over the past year, it has increased by +$3.77 million (+29.15%).PRTK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRTK TTM EBITDA
-$43.40 M
+$3.77 M+8.00%
30 June 2023
Summary:
As of January 21, 2025, PRTK TTM earnings before interest, taxes, depreciation & amortization is -$43.40 million, with the most recent change of +$3.77 million (+8.00%) on June 30, 2023. Over the past year, it has increased by +$23.76 million (+35.38%).PRTK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRTK EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.4% | +29.1% | +35.4% |
| 3 y3 years | +59.9% | +48.8% | +52.4% |
| 5 y5 years | +45.2% | +65.7% | +61.3% |
PRTK EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -3475.9% | -119.7% | -220.4% |
Paratek Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$9.17 M(-41.1%) | -$43.40 M(-8.0%) |
| Mar 2023 | - | -$15.56 M(+533.5%) | -$47.17 M(+5.1%) |
| Dec 2022 | -$44.90 M(+10.4%) | -$2.46 M(-84.9%) | -$44.90 M(-35.5%) |
| Sept 2022 | - | -$16.21 M(+25.3%) | -$69.63 M(+3.7%) |
| June 2022 | - | -$12.94 M(-2.6%) | -$67.16 M(+67.7%) |
| Mar 2022 | - | -$13.29 M(-51.1%) | -$40.04 M(-1.6%) |
| Dec 2021 | -$40.69 M(-46.3%) | -$27.18 M(+97.7%) | -$40.69 M(+22.9%) |
| Sept 2021 | - | -$13.75 M(-197.0%) | -$33.10 M(-5.0%) |
| June 2021 | - | $14.18 M(-201.8%) | -$34.86 M(-47.9%) |
| Mar 2021 | - | -$13.93 M(-28.9%) | -$66.93 M(-11.6%) |
| Dec 2020 | -$75.72 M(-32.4%) | -$19.60 M(+26.4%) | -$75.72 M(-3.6%) |
| Sept 2020 | - | -$15.50 M(-13.4%) | -$78.56 M(-13.8%) |
| June 2020 | - | -$17.89 M(-21.2%) | -$91.11 M(-11.0%) |
| Mar 2020 | - | -$22.72 M(+1.3%) | -$102.42 M(-8.6%) |
| Dec 2019 | -$112.09 M(+11.1%) | -$22.44 M(-20.0%) | -$112.09 M(+3.1%) |
| Sept 2019 | - | -$28.05 M(-4.0%) | -$108.75 M(-0.6%) |
| June 2019 | - | -$29.21 M(-9.8%) | -$109.39 M(+2.3%) |
| Mar 2019 | - | -$32.38 M(+69.6%) | -$106.91 M(+6.3%) |
| Dec 2018 | -$100.87 M(+23.1%) | -$19.10 M(-33.5%) | -$100.58 M(-1.1%) |
| Sept 2018 | - | -$28.70 M(+7.4%) | -$101.67 M(+9.8%) |
| June 2018 | - | -$26.73 M(+2.6%) | -$92.56 M(+13.2%) |
| Mar 2018 | - | -$26.06 M(+29.0%) | -$81.79 M(-0.2%) |
| Dec 2017 | -$81.97 M(-22.8%) | -$20.19 M(+3.1%) | -$81.97 M(-4.7%) |
| Sept 2017 | - | -$19.59 M(+22.8%) | -$86.02 M(-3.2%) |
| June 2017 | - | -$15.95 M(-39.2%) | -$88.87 M(-12.9%) |
| Mar 2017 | - | -$26.24 M(+8.3%) | -$102.05 M(-3.8%) |
| Dec 2016 | -$106.11 M(+52.9%) | -$24.24 M(+8.0%) | -$106.11 M(+3.9%) |
| Sept 2016 | - | -$22.45 M(-22.9%) | -$102.11 M(-0.8%) |
| June 2016 | - | -$29.13 M(-3.9%) | -$102.89 M(+15.2%) |
| Mar 2016 | - | -$30.30 M(+49.7%) | -$89.31 M(+28.7%) |
| Dec 2015 | -$69.38 M(+310.0%) | -$20.24 M(-12.9%) | -$69.38 M(+23.6%) |
| Sept 2015 | - | -$23.22 M(+49.3%) | -$56.12 M(+52.7%) |
| June 2015 | - | -$15.55 M(+50.1%) | -$36.76 M(+50.0%) |
| Mar 2015 | - | -$10.36 M(+48.4%) | -$24.50 M(+44.8%) |
| Dec 2014 | -$16.92 M(-30.4%) | -$6.98 M(+80.9%) | -$16.92 M(+9.5%) |
| Sept 2014 | - | -$3.86 M(+17.1%) | -$15.45 M(-5.0%) |
| June 2014 | - | -$3.30 M(+18.6%) | -$16.26 M(-2.4%) |
| Mar 2014 | - | -$2.78 M(-49.5%) | -$16.66 M(-31.5%) |
| Dec 2013 | -$24.32 M | -$5.51 M(+17.8%) | -$24.32 M(-3.8%) |
| Sept 2013 | - | -$4.68 M(+26.4%) | -$25.28 M(+61.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$3.70 M(-64.5%) | -$15.65 M(-7.9%) |
| Mar 2013 | - | -$10.43 M(+61.2%) | -$16.99 M(+46.1%) |
| Dec 2012 | -$11.63 M(+241.3%) | -$6.47 M(-230.7%) | -$11.63 M(-4965.3%) |
| Sept 2012 | - | $4.95 M(-198.4%) | $239.00 K(-102.5%) |
| June 2012 | - | -$5.03 M(-0.8%) | -$9.60 M(+43.6%) |
| Mar 2012 | - | -$5.08 M(-194.1%) | -$6.69 M(+96.2%) |
| Dec 2011 | -$3.41 M(-60.9%) | $5.39 M(-210.4%) | -$3.41 M(-69.8%) |
| Sept 2011 | - | -$4.89 M(+130.8%) | -$11.27 M(+25.2%) |
| June 2011 | - | -$2.12 M(+17.9%) | -$9.00 M(+2.2%) |
| Mar 2011 | - | -$1.80 M(-27.2%) | -$8.81 M(+1.0%) |
| Dec 2010 | -$8.72 M(-54.8%) | -$2.47 M(-5.8%) | -$8.72 M(+4.2%) |
| Sept 2010 | - | -$2.62 M(+36.1%) | -$8.37 M(-11.9%) |
| June 2010 | - | -$1.93 M(+12.6%) | -$9.49 M(-35.4%) |
| Mar 2010 | - | -$1.71 M(-19.1%) | -$14.70 M(-23.8%) |
| Dec 2009 | -$19.30 M(+8.4%) | -$2.11 M(-43.6%) | -$19.30 M(-73.3%) |
| Sept 2009 | - | -$3.75 M(-47.5%) | -$72.28 M(-4.3%) |
| June 2009 | - | -$7.13 M(+13.1%) | -$75.57 M(+244.7%) |
| Mar 2009 | - | -$6.31 M(-88.6%) | -$21.92 M(+24.1%) |
| Dec 2008 | -$17.80 M(-51.2%) | -$55.10 M(+683.6%) | -$17.66 M(-152.7%) |
| Sept 2008 | - | -$7.03 M(-115.1%) | $33.52 M(-7.0%) |
| June 2008 | - | $46.52 M(-2373.5%) | $36.04 M(-233.3%) |
| Mar 2008 | - | -$2.05 M(-47.7%) | -$27.04 M(-25.4%) |
| Dec 2007 | -$36.50 M(+13.9%) | -$3.91 M(-13.4%) | -$36.26 M(-11.7%) |
| Sept 2007 | - | -$4.52 M(-72.7%) | -$41.07 M(-6.8%) |
| June 2007 | - | -$16.56 M(+47.0%) | -$44.05 M(+25.1%) |
| Mar 2007 | - | -$11.27 M(+29.1%) | -$35.22 M(+11.0%) |
| Dec 2006 | -$32.05 M(+31.7%) | -$8.72 M(+16.4%) | -$31.72 M(-33.8%) |
| Sept 2006 | - | -$7.50 M(-3.1%) | -$47.90 M(+18.6%) |
| June 2006 | - | -$7.74 M(-0.3%) | -$40.39 M(+23.7%) |
| Mar 2006 | - | -$7.76 M(-68.8%) | -$32.64 M(+31.3%) |
| Dec 2005 | -$24.34 M(+30.2%) | -$24.91 M(<-9900.0%) | -$24.86 M(+27.0%) |
| Sept 2005 | - | $14.00 K(0.0%) | -$19.58 M(+1.4%) |
| June 2005 | - | $14.00 K(0.0%) | -$19.31 M(+1.4%) |
| Mar 2005 | - | $14.00 K(-100.1%) | -$19.05 M(+1.4%) |
| Dec 2004 | -$18.69 M(-1505.3%) | -$19.62 M(-7106.8%) | -$18.78 M(-2335.6%) |
| Sept 2004 | - | $280.00 K(0.0%) | $840.00 K(+50.0%) |
| June 2004 | - | $280.00 K(0.0%) | $560.00 K(+100.0%) |
| Mar 2004 | - | $280.00 K | $280.00 K |
| Dec 2003 | $1.33 M(-122.6%) | - | - |
| Dec 2002 | -$5.88 M(+257.1%) | - | - |
| Dec 2001 | -$1.65 M | - | - |
FAQ
- What is Paratek Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Paratek Pharmaceuticals?
- What is Paratek Pharmaceuticals annual EBITDA year-on-year change?
- What is Paratek Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Paratek Pharmaceuticals?
- What is Paratek Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Paratek Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Paratek Pharmaceuticals?
- What is Paratek Pharmaceuticals TTM EBITDA year-on-year change?
What is Paratek Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PRTK is -$44.90 M
What is the all time high annual EBITDA for Paratek Pharmaceuticals?
Paratek Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $1.33 M
What is Paratek Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, PRTK annual earnings before interest, taxes, depreciation & amortization has changed by -$4.21 M (-10.36%)
What is Paratek Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PRTK is -$9.17 M
What is the all time high quarterly EBITDA for Paratek Pharmaceuticals?
Paratek Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $46.52 M
What is Paratek Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, PRTK quarterly earnings before interest, taxes, depreciation & amortization has changed by +$3.77 M (+29.15%)
What is Paratek Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PRTK is -$43.40 M
What is the all time high TTM EBITDA for Paratek Pharmaceuticals?
Paratek Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $36.04 M
What is Paratek Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, PRTK TTM earnings before interest, taxes, depreciation & amortization has changed by +$23.76 M (+35.38%)